nelfinavir has been researched along with thyroxine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kessler, HA; Nerad, JL | 1 |
| de Groot, R; Gaakeer, MI; Geelen, SP; Hartwig, NG; Lamberts, SW; Van Rossum, AM; Verweel, S; Wolfs, TF | 1 |
| Burns-Naas, LA; Capen, CC; Chen, M; Cook, JC; Evering, W; Furman, G; Gasser, R; Ivett, JL; Jessen, B; McClain, RM; Ryan, TE; Shetty, B; Stevens, G; Theiss, JC; Webber, S; Wu, E; Zorbas, M | 1 |
1 review(s) available for nelfinavir and thyroxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for nelfinavir and thyroxine
| Article | Year |
|---|---|
Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.
Topics: Antiretroviral Therapy, Highly Active; Body Height; Body Mass Index; CD4 Lymphocyte Count; Child, Preschool; Female; Growth; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydrocortisone; Infant; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Nelfinavir; Serum Albumin; Thyroxine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2003 |
4 other study(ies) available for nelfinavir and thyroxine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Reverse Transcriptase Inhibitors; Thyroxine; Zidovudine | 2001 |
Increase in thyroid follicular cell tumors in nelfinavir-treated rats observed in a 2-year carcinogenicity study is consistent with a rat-specific mechanism of thyroid neoplasia.
Topics: Adenocarcinoma, Follicular; Administration, Oral; Animals; Aryl Hydrocarbon Hydroxylases; Carcinogenicity Tests; Cell Survival; Cells, Cultured; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Gene Expression; Glucuronosyltransferase; Hepatocytes; HIV Protease Inhibitors; Hyperplasia; Longevity; Male; Nelfinavir; Rats; Rats, Sprague-Dawley; RNA, Messenger; Species Specificity; Thyroid Gland; Thyroid Hormones; Thyroid Neoplasms; Thyroxine | 2005 |